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Abstract
Protein 4.1 (80 kD) interacts with spectrin and short actin
filaments to form the erythrocyte membrane skeleton. Muta-
tions of spectrin and protein 4.1 are associated with elliptocy-
tosis or spherocytosis and anemia of varying severity. We ana-
lyzed two mutant protein 4.1 molecules associated with ellip-
tocytosis: a high molecular weight 4.1 (95 kD) associated with
mild elliptocytosis without anemia, and a low molecular weight
4.1 (two species at 68 and 65 kD) associated with moderate
elliptocytosis and anemia. 4.1j9 was found to contain a - 15-
kD insertion adjacent to the spectrin/actin binding domain
comprised, at least in part, of repeated sequence. 4.68165 was
found to lack the entire spectrin-actin binding domain. The
mechanical stability of erythrocyte membranes containing
4.195 was identical to that of normal membranes, consistent
with the presence of an intact spectrin-actin binding domain in
protein 4.1. In contrast, membranes containing 4.168/65 have
markedly reduced mechanical stability as a result of deleting
the spectrin-actin binding domain. The mechanical stability of
these membranes was improved following reconstitution with
normal 4.1. These studies have thus enabled us to establish the
importance of the spectrin-actin binding domain in regulating
the mechanical stability of the erythrocyte membrane. (J. Clin.
Invest. 1990. 86:516-523.) Key words: erythrocytes * protein
4.1 * elliptocytosis * mutations
Introduction
The erythrocyte membrane is composed of a lipid bilayer,
transmembrane proteins which include the glycophorins and
band 3, the anion channel, and a membrane skeleton. The
major components of the membrane skeleton are spectrin,
protein 4.1 (hereafter referred to as 4.1), ankyrin, and short
actin filaments, all of which interact to form an extended net-
work underlying the lipid bilayer. Specific associations be-
tween ankyrin and band 3 and between 4.1 and glycophorin
attach the skeletal network to the lipid bilayer. The membrane
skeleton confers upon the red cell its shape and the properties
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of deformability and mechanical stability necessary for its
120-d lifespan in the microcirculation. The concept that the
membrane skeleton plays an important role in determining
shape and deformability of the red cell has been supported by
discoveries in recent years of deficiencies and mutant forms of
spectrin, 4.1, and ankyrin in erythrocytes of patients with he-
reditary spherocytosis and elliptocytosis.
Protein 4.1 deficiency was first reported in three children of
a consanguineous marriage who had transfusion-dependent
hemolytic elliptocytosis (HE)' (1, 2). Erythrocytes of the af-
fected children were entirely lacking in 4.1, while the parents
had partial deficiency of 4.1 and mild elliptocytosis. Erythro-
cyte membranes lacking 4.1 were found to exhibit markedly
decreased mechanical stability (2). Reconstitution of 4. 1-defi-
cient red cells with purified 4.1 by exchange hemolysis restored
normal stability to the 4.1-deficient membranes (3). A subse-
quent study by Alloisio et al. (4) of 10 families from southeast-
ern France and North Africa with typical mild elliptocytosis
revealed partial 4.1 deficiency in seven affected members of
four families.
It has long been recognized that HE is inherited in linkage
with Rh blood group phenotype in a subset of families (5). This
association has now been explained by assignment of the 4.1
gene to chromosome 1 in close proximity to the genes for Rh
blood group types (6). Agre and colleagues (7) have described
three distinct variants of erythrocyte 4.1 associated with HE
that are inherited in linkage with the Rh blood group type.
Affected members of family C of Italian ancestry have erythro-
cytes with reduced content of 4.1 of normal molecular weight
(- 80 kD). Affected members of family N, of Scottish-Irish
descent, are heterozygous for a high molecular weight form of
4.1 at - 95 kD (4.195). Affected members of family G, of
Italian descent, are heterozygous for normal 4.1 8 and two low
molecular weight forms of 4.1 at - 68 and 65 kD (4.168/65). In
this family, the presence of 4.168/65 is associated with moder-
ately severe hemolytic elliptocytosis. We describe here the site
and nature of the insertion resulting in 4.195, the deletion(s)
resulting in 4.168/65, and the functional consequences of these
mutations. The mutant 4.1 proteins were examined by chemi-
cal and enzymatic cleavages originally used by Leto and Mar-
chesi (8) to characterize normal 4.1. In a companion paper, the
mutations are further characterized by sequencing of PCR-
amplified mRNA around regions of cDNA determined from
the protein data to be the sites of insertion or deletion.
1. Abbreviations used in this paper: DFP, diisopropylfluorophosphate;
HE, hemolytic elliptocytosis; HMW, high molecular weight; IEP, iso-
electric point; LMW, low molecular weight; NTCB, nitrothiocyano-
benzoic acid.
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Methods
Extraction and purification ofprotein 4.1.
Red cells were washed, lysed, and white ghosts were dialyzed at low
ionic strength (0.1 mM EDTA, 0.1 mM diisopropylfluorophosphate,
DFP, pH 9.0, at 40C) to remove spectrin, as previously described (8).
The spectrin-depleted vesicles were homogenized and suspended in 5
mM NaH2 P04, 1 mM EDTA, 1 M KCI, 1 mM DFP, and 0.05 mM
phenylmethylsulfonylfluoride (PMSF), pH 7.5, incubated overnight at
4VC and then at 370C for 30 min to extract 4.1, ankyrin (band 2.1) and
band 6. The extract was centrifuged at 100,000 g, and the supernatant
was dialyzed against the same buffer but with KCI concentration re-
duced to 20 mM. Protein 4.1 was separated from ankyrin and band 6
by chromatography on Whatman DE 52 (Whatman Inc., Clifton, NJ)
using a linear KCl gradient of20 to 300mM KCI in 5 mM NaH2PO4, 1
mM EDTA, 0.5 mM (i-mercaptoethanol, pH 7.6. The purified 4.1 was
dialyzed into 5 mM NaH2PO4, 1 mM EDTA, and 200 mM KCl.
Proteolytic cleavages ofprotein 4.1
Cysteine-specific cleavage of protein 4.1 was performed as previously
described (8). Briefly, intact IOVs or 4.1 electroeluted from acrylamide
gels were incubated in 7.5 M guanidine HC1, 0.2 M Tris, 1 mM EDTA,
at pH 8.0 in the presence of nitrothiocyanobenzoic acid (NTCB) at
0.225 ug/Ml (for 4.1 extracts) or 0.6 ug/,l (for IOVs) at room tempera-
ture for 1 hr. The pH was then adjusted to 9.0 with Tris base and the
samples were incubated overnight at 37°C. The reaction was stopped
with 10 mM Tris, 1.0 mM P-mercaptoethanol, pH 8.0, and lyophi-
lized.
Chymotryptic digestion of purified 4.1 was performed in 10 mM
Tris HC1, 1.0 mM ,B-mercaptoethanol, pH 8.0 for 30 min at 20C at
ratios of chymotrypsin:4.1 ranging from 1:100 to 1:500 (8). The diges-
tion was stopped by the addition of 1 mM DFP and lyophilization.
Cyanogen bromide (CNBr) cleavage of purified, lyophilized 4.1
(150-200 Mg) was performed in 70% formic acid containing 200 mol
CNBr per mol methionine in 4.1 and incubated for 24 h at 37°C in the
presence of argon. The digests were then diluted 1:20 with distilled
water and lyophilized.
Membrane protein analysis
Electrophoresis in one dimension ofred cell ghosts and NCTB peptides
was performed on SDS-PAGE according to Laemmli (9) followed by
staining with Coomassie blue or transfer to nitrocellulose membranes
for immunoblotting. Two-dimensional electrophoresis (isoelectric fo-
cusing-SDS-PAGE, IEF/SDS) was performed as described for spectrin
tryptic peptides (10), except that the focusing gel was run in the reverse
direction (acid to base).
Anti-4.1 antibodies. Antibodies to five synthetic peptides of 4.1,
ranging in size from 15 to 26 residues and encompassing the four
chymotryptic domains of4.1 were raised in New Zealand white rabbits
(see Fig. 1). All antibodies generated were affinity-purified on Sepha-
rose-conjugated to the appropriate peptide antigen.
Immunoblots. Peptides of4.1 resulting from enzymatic or chemical
cleavages were electrophoresed in one or two dimensions, transferred
to nitrocellulose (Schleicher and Schuell, Inc., Keene, NH) and blotted
with polyclonal (rabbit) antibody generated either to intact 4.1 or to
synthetic peptides derived from one of the four chymotryptic domains
of 4.1, incubated with '231-Staph A protein (Amersham Corp., Arling-
ton Heights, IL, and Pharmacia Fine Chemicals, Piscataway, NJ), and
exposed to Kodak XAR film for times varying from 3 h to 1 wk.
NHrterminal sequence determinations. One- or two-dimensional
SDS gels of chymotryptic peptides of 4.1 were prepared with recrystal-
lized SDS and transferred to Immobilon0 membranes (Polyvinylidene
difluoride; Millipore Corp., Bedford, MA) in 25 mM Tris, 190 mM
glycine, 20% methanol at 50 V for 16 to 24 h. The membranes were
stained with Coomassie blue for 5 min, destained, dried, and stored at
-20°C. NH2-terminal sequence was performed on selected peptides
cut from these membranes.
Membrane mechanical stability measurements
Resealed membranes for mechanical stability measurements were
prepared by a procedure adapted from Johnson (1 1). The erythrocytes
were washed three times in 5 mM Tris, 140 mM NaCl (pH 7.4), and
then lysed in 40 vol of 7 mM NaCl and 5 mM Tris (pH 7.4). The
membranes were then pelleted by centrifugation, resuspended in 10
vol of 5 mM Tris and 140mM NaCl (pH 7.4) and incubated 30 min at
370C for resealing.
For mechanical stability measurements, 100 Ml ofa 40% membrane
suspension was mixed with 3 ml dextran (40,000 mol wt, 35 g/100 ml
in 10 mM phosphate buffer, pH 7.4, viscosity 95 centipoise) and sub-
jected continuously to 750 dyn/cm2 in the ektacytometer (12). Under
this stress, the membranes progressively fragment, generating unde-
formable spheres. This process is detected as a time-dependent de-
crease in the DI. The time required for the DI to fall to 60% of its
maximum value is termed T60 and is taken as a measure ofmembrane
stability.
Protein 4.1 reconstitution experiment
To incorporate purified normal protein 4.1 into the membranes with
mutant protein 4.1, we modified the technique of exchange hemolysis
described by Clark and Shohet ( 13). In brief, elliptocytic erythrocytes
were first washed with the isotonic sodium phosphate buffer (pH 7.4,
290 mosmol/kg) and then lysed in 40 vol ofice-cold hypotonic sodium
phosphate buffer (pH 7.4, 40 mosmol/kg). The membranes were col-
lected by centrifugation at 39,000 g for 2 min at 0°C. Four-tenths
milliliter of purified protein 4.1 solution of a defined concentration
was added to 0.4 ml of packed membranes. The mixture was gently
stirred at 0°C for 20 min. Following this incubation in the cold, 0.1 ml
of a mixture of KCI, MgC12 and dithiothreitol (DTT) was added to the
membrane suspension to give a final concentration of 100mM KC1, 1
mM MgCl2 and 1 mM DTT. The membranes were then incubated at
37°C for 60 min to allow them to reseal. Incorporation of protein 4.1
into the protein 4.1-deficient membranes was confirmed by SDS-
PAGE analysis of the reconstituted membranes.
Results
Purification of 4.1 from erythrocytes of affected members of
family N with elliptocytosis yielded a 4.1-species of - 95 kD
and normal 4.18 in nearly equal proportions, as previously
described by McGuire et al. (7). The high molecular weight
(HMW) 4.1 reacts with all five antibodies generated to syn-
thetic peptides ofthe four chymotryptic domains (Fig. 1), sug-
gesting that the high molecular weight (HMW) species con-
tains all normal domains of 4.1 plus an insertion of - 15 kD.
We will henceforth refer to the 4.1 of affected members of
family N as 4. 1W0+95 and to the isolated HMW 4.1 as 4.195.
NTCB Peptides of 4. 180+95. Nitrothiocyanobenzoic acid
(NTCB) cleaves proteins at cysteine residues. Since the seven
cysteine residues in protein 4.1 are clustered with the NH2-ter-
minal chymotryptic 30 kD domain (8), comparison of 4.180
and 4.195 NTCB peptides should indicate whether or not the
insertion resulting in 4.195 is NH2-terminal. Proteins 4.1 8° and
4.195 were electroeluted from acrylamide gel slices and cleaved
with NTCB as described in Methods. NTCB peptides of 4.180
and 4.195 were immunoblotted with antibody to intact 4.1 and
to a synthetic peptide ofthe NH2-terminal 30 kD domain. The
short NH2-terminal NTCB peptides of 4.180 and 4.19" were
identical in size, while the larger (COOH-terminal) NTCB
peptides of 4.195 from a ladder - 15 kD larger than those of
4.18 (data not shown). The conclusion from this approach was
that the insertion resulting in 4.195 is not NH2-terminal, nor is
it within the NHrterminal 30 kD chymotryptic domain.
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CGNG - Figure 1. Redcell ghostsfrom a
control (C:4.180), patient N (hetero-
* m g_ Z zygous for high molecular weight
* t_ __ * *=_ dD Z _ form of protein 4.1:4. 1+9),and
patient G (heterozygous for low mo-
lecular weight forms of protein
4.1:4.180+68/65), immunoblotted with
antibody to synthetic peptides from
Anti- 30 16 10a 10b 24 each of the chymotryptic domains,
shown in the model below. The
amino acid sequence of the syn-
thetic peptides of chymotryptic do-
mains of 4.1 to which polyclonal
antibodies were raised is as follows:
| m 1 lj |30 kD peptide (GSYTIQSELG-
a b DYDPELHGVDYVSDC); 16 kD
30 16 10 24 peptide (TQAQTRQASALIDR-
PAPHFERC); lOa peptide
(KKKRERLDGENIYIRC); lOb peptide (MESVPEPRDSEWDKC); and 24 kD peptide (GVLLTAQTITSETPSSTTTTQITKC).
Chymotryptic peptides of 4. 180 and 4.195. Chymotryptic
cleavage of 4.1 at enzyme:substrate ratios of - 1/500 to 1/200
occurs primarily at three sites, producing four major peptides
as described by Leto et al. (8) and shown in Fig. 2, a and b.
Proceeding from the NH2 terminus, these peptides are as fol-
lows: (a) a basic 30-kD fragment containing all cysteines in
4.1; (b) a 16-kD peptide of intermediate isoelectric point; (c)
an 8- to 10-kD peptide containing the spectrin-actin binding
site and a site of phosphorylation by cAMP-dependent protein
kinase (4, 14-16); and (d) an acidic - 24 kD COOH-terminal
peptide. Under the mild conditions of digestion used, chymo-
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sulting in the presence of overlapping peptides at - 34 kD (24
+ 10), 46kD(30+ 16), 50 kD (24 + 10 + 16), and. - 56
(30 + 16 + 10) (8).
Fig. 2 a shows two-dimensional maps of chymotryptic
peptides of 4.18 and 4.180+95 immunoblotted with anti-4.1
antibody, and a diagrammatic model of the chymotryptic do-
mains of 4.1. Both peptide maps show 24- and 34-kD peptides
with similar acidic isoelectric points. In addition, the chymo-
tryptic map of 4. 180+95 has a new 44-kD peptide with the same
isoelectric points (IEP) as the normal 34-kD peptide, and a
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Figure 2. (a) Two-dimensional maps of the chymotryptic peptides of 4.180 (top) and 4.180+95 (bottom): immunoblot of chymotryptic maps with
antibody to 4.1. Arrows mark peptides unique to 4.195. Chymotryptic peptides of normal 4.1 are shown in the models below. Numbers indicate
apparent kD of 4.1 peptides. (b) Two-dimensional (IEF/SDS) maps of chymotryptic peptides of 4. 180 (top) and 4.195 (bottom) stained with
Coomassie blue. Numbers indicate apparent kilodaltons of peptides. Arrows mark peptides unique to 4.195.
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Fig. 2 b compares Coomassie blue-stained chymotryptic
maps of normal 4.180 and 4. 19 isolated by electroelution from
acrylamide gel slices. The digest of 4. 19 has the normal acidic
24-kD peptide, lacks the normal 34-kD peptide, and demon-
strates the new 44-kD peptide seen in Fig. 2 a. 4. 195 also has a
new - 66-kD basic peptide which is thought to represent an
addition of -10 kD to the normal 56-kD peptide. Taken
together, the results of NTCB and chymotryptic cleavage of
4.19 indicated that the inserted sequence resulting in 4.195 is
neither NH2-terminal nor COOH-terminal, but that it is adja-
cent to the 10-kD actin-spectrin binding domain and that the
new 44, 60, and 66 chymotryptic peptides in 4.195 contain part
or all of the insert. (See linear model of 4.1 in Fig. 2 a.)
Cyanogen bromide (CNBr) peptides of4.180 and 4.180+95. In
an attempt to localize more precisely the insert resulting in
4.195, normal and mutant 4.1 were digested with cyanogen
bromide (CNBr), which cleaves at methionine residues. The
10-kD chymotryptic domain has two methionines, and it was
anticipated that the size of CNBr peptides generated from
normal and mutant 4.1 and their reactivity with antibodies to
the 10 kD domain would help to determine the site ofinsertion
in 4.195. Fig. 3 shows two-dimensional maps ofCNBr peptides
of 4.180 and 4.180+95 immunoblotted with antibodies to syn-
thetic peptides from the NH2- and COOH-terminal regions of
the 10-kD domain, termed lOa and lOb, respectively. The
diagram below the figure compares chymotryptic and CNBr
peptide domains, and locates lOa and lOb peptides. The CNBr
peptides of 4.180+95 include a cluster of basic peptides at
- 12-17 kD not present in normal 4.1 digests that are reactive
with antibody to lOa but not to lOb, suggesting that the inser-
tion producing 4.195 is NH2-terminal to the normal I0-kD
domain, or that CNBr cleavage at the methionine residue
within the lOb synthetic peptide interferes with its recognition
by the anti- lOb antibody.
28-
An attempt to determine NH2-terminal sequence of
unique 4.195 CNBr peptides was unsuccessful, presumably due
to chemical damage of their NH2-termini. However, extensive
chymotryptic digestion of 4.180+95 generated a peptide with
size and IEP comparable to the 12 kD CNBr peptides, one
which is not found in similar digests of 4.18 (data not shown).
The NH2-terminal four residues of this unique 1 2-kD peptide
(Fig. 4) are EAAQ, identical to the last four residues ofthe first
exon within the 24 kD domain of normal 4.180 (17, 18). These
four residues are followed by 20 residues of the 10-kD spec-
trin-actin binding domain, beginning at a known splice site for
the first exon in the 10 kD region: *KKRER ([17-19] see Fig.
4). The sequence EAAQ in the intact 24 kD domain is nor-
mally preceded by a tryptophan, consistent with the observed
chymotryptic cleavage at that site.
The NH2-terminal sequence of the 44-kD peptide unique
to 4. 19 was found to be identical to the NH2-terminus of the
24-kD domain (Fig. 4). These data suggested that the insertion
producing 4.195 is the result of partial repeat of the 24-kD
domain, and possibly of the 10-kD domain (see Discussion).
Characterization of mutant low molecular weight 4.168/65.
Fig. 5 shows partially purified 4.1 from patient G, originally
described by McGuire and Agre (7). In addition to 4.180, there
are two low molecular weight (LMW) species of 68 and
- 65 kD which together comprise less than halfofthe total 4.1
present. Normal protein 4.18 from patient G reacts with all
five antibodies generated to synthetic peptides ofthe four chy-
motryptic domains (Fig. 1). The LMW species of 4.1 from
patient G (4.168/65) reacts with antibodies to the 30-, 16-, and
24-kD domains (Fig. 1), but shows no reaction with two anti-
bodies to the I0-kD domain (lOa and lOb), suggesting that the
entire spectrin-actin binding domain is missing.
Chymotryptic peptides of 4.1J6865. The boundaries of the
















30 maps of cyanogen bromide
(CNBr) peptides of 4. 180 and
4. 180+95 immunoblotted with
antibody to synthetic pep-
tides of the 10-kD chymo-
tryptic domain termed lOa
and lOb. The short vertical
lines in the models below in-
dicate sites of cleavage of 4.1
by chymotrypsin and CNBr,
and identifies antigens lOa
and lOb.
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those used to study 4.195. Chymotryptic peptides of 4.180+68/65
electrophoresed in two dimensions and immunoblotted with
antibodies to the 16- and 24-kD chymotryptic domains (Fig. 6)
show the normal 24-, 34-, and 50-kD peptides as well as new
peptides of - 40 kD (circled) not present in normal 4.1 maps.
The new 40-kD peptides in 4.168/65 presumably represent fu-
sion peptides of the 16- and 24-kD domains, the result of
deletion of part or all of the intervening 10 kD spectrin-actin
binding domain. These studies did not identify the - 3-kD
difference between the two LMW mutants.
Mechanical stability of erythrocyte membranes. Ektacyto-
metric measurement of mechanical stability of membranes
derived from erythrocytes with the high and low molecular
variants of 4.1, as well as membranes with reduced content of
normal 4.1 is shown in Fig. 7a. The rate of decline of defor-
mability index (a measure of mechanical stability) of mem-
branes with high molecular weight 4.1 was identical to that of
normal membranes, implying that these membranes exhibit
normal mechanical stability. In contrast, the deformability
index ofmembranes with low molecular weight 4.1 declined at
a much faster rate, implying decreased mechanical stability.
The observed decrease in mechanical stability of these mem-
branes was comparable to that of membranes with a 50% re-
C G
Figure 5. Protein 4.1
purified from red cells
of patient G (heterozy-
gous for low molecular
weight form of protein
4.1) and normal red
cells (C). Numbers indi-
cate apparent kilodal-





Figure 4. NH2-terminal sequence of 12
and 44 kD chymotryptic peptides
unique to 4.1is. The position of related
sequence of 4.180 are shown with re-
spect to the normal chymotryptic map
and to the known exon structure. exon
M, *splice sites, 30, 16, 10, 24, chymo-
tryptic domains.
IGQIP
duction in membrane content ofnormal 4.1. These data imply
that, while the high molecular variant (4.195) functions nor-
mally in bestowing mechanical stability to the membrane, the
low molecular weight variant (4.168/65) is dysfunctional.
To assess if normal mechanical stability could be restored
to unstable membranes with a low molecular weight variant of
4.1, we reconstituted these membranes with purified normal
4.1. As shown in Fig. 7 b, as increasing concentrations of
purified normal 4.1 were used for reconstitution, the mechan-
ical stability progressively improved. Maximal increase in me-
chanical stability was seen at a protein concentration of 220
,gg/ml, when the mechanical stability of the reconstituted
membranes increased twofold. Further increases in concen-
tration of normal 4.1 used during reconstitution did not result
in further improvement in mechanical stability. This is in
contrast to membranes with quantitative deficiency of protein
4.1, in which complete normalization of mechanical stabil-
ity could be achieved following reconstitution with normal
4.1 (3).
Discussion
Homozygous deficiency of 4.1 in the erythrocytes of three
offspring of a consanguineous marriage resulted in severe he-
molytic elliptocytosis demonstrating an important role for 4.1
in maintaining normal shape, membrane mechanical stability
and lifespan (1-3). Since this original description ofan associa-
tion between 4.1 and hereditary elliptocytosis, a number of
additional families have been identified in which elliptocytic
phenotype was linked to either a qualitative defect or a quan-
titative deficiency of protein 4.1 (4, 7, 20-22). However, no
information is currently available regarding the biochemical
defect or structural sequelae of these mutant 4.1 proteins.
Our strategy for the characterization of the mutant 4.1
molecules was based on the approach used by Leto et al. for
structural characterization of normal 4.180 (8, 14, 15). To lo-
cate sites of insertion or deletion, peptides of normal 4. 180 and
the mutant 4. 195 and 4.168/65 produced by enzymatic and
chemical cleavages were mapped in one or two dimensions
and analyzed by immunochemical analysis using antibodies to
five synthetic peptides that span the entire normal 4.1 mole-
cule. These data and NH2-terminal sequencing of a small chy-
motryptic peptide (- 12 kD) unique to 4. 195 suggested that
the insertion involved repeated sequence of the 24-kD do-
main, located anomalously NH2-terminal to the 10-kD spec-
trin-actin binding domain. However, the size of the 4. 195 indi-
cated that the insertion involved more than repeat of - 6-kD
ofthe 24-kD domain, and the preservation ofits chymotryptic
domain structure suggested that the entire insertion consisted











-24 Figure 6. Chymotryptic maps of 4.18° and
4.180+6865 immunoblotted with antibodies
to synthetic peptides of the 16- and 24-kD
chymotryptic domains of 4.1. Numbers at
the right indicate apparent kilodaltons of
peptides. Circled peptides are unique to
4 i80+68/65 The drawing below suggests the
boundaries of the new 40-kD peptides.
of repeated sequence. The small size (12-17 kD) of the lOa
reactive CNBr fragments unique to 4.195 and the position of
available methionines for cleavage, further suggested that the
repeat included all or part of the 10-kD domain. The LMW
variant, 4.168/65, was found to lack most or all of the spectrin-
actin binding domain. The precise boundaries ofthe insertion
in 4. and deletion in 4.168/65 have been defined by molecular
cloning of mutant mRNA, sequencing using PCR techniques,
and these data are described in a companion paper.
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Figure 7. (a) Mechanical stability of erythrocyte membranes. Resealed ghosts prepared from normal and mutant protein 4.1 cells were exposed
to 750 dyns/cm2 in the ektacytometer and decline ofthe deformability index (DI) was measured as a function of time. The rate ofDI decline is
a measure ofmembrane mechanical stability. Membranes of cells with high molecular weight variant of 4.1 (4.195) fragmented normally, while
membranes of cells with low molecular weight variant (4.168/65) fragmented more rapidly than did normal membranes. Membranes partially
deficient in normal 4.1 also fragmented at a rate similar to that ofmembranes with a low molecular variant. (b) Restoration of mechanical sta-
bility to membranes with a low molecular weight 4.1 variant. Ghosts prepared from these cells were incubated with 0, 0.05, 0.1 1, and 0.22
mg/ml of normal 4.1 before resealing. Increasing the concentration of normal 4.1 resulted in a decrease in the rate of fragmentation, implying
improved mechanical stability.













ized involve the spectrin-actin binding domain of 4.1. In the
high molecular weight variant, there appears to be duplication
of this important functional domain, resulting in 4.19 having
two binding sites for interaction with spectrin and actin. In
contrast, the low molecular variant appears to have a deletion
of this functional domain, resulting in 4.168/65 having no
binding site for interaction with spectrin and actin.
The structural and functional changes in erythrocytes with
alterations in the spectrin-actin binding domain of mutant
4.1's have enabled us to elucidate the function of this impor-
tant structural component of the erythrocyte membrane. The
finding that erythrocyte membranes containing 4.195 exhibit
normal mechanical stability implies that the presence of an
additional binding domain for spectrin and actin on this mole-
cule does not alter its ability to interact normally with the
other structural components of the membrane. Moreover, the
absence of fragmented cells in circulation and the near-normal
hematologic status of these individuals implies that erythro-
cytes with a high molecular weight variant of 4.1 also exhibit
normal function in vivo.
These findings are in marked contrast to those seen with
erythrocytes with a low molecular weight variant of 4.1. The
mechanical stability of membranes of these cells is markedly
decreased. In fact, our finding that the mechanical stability of
these membranes is very similar to that of membranes with a
50% reduction in 4.1 content implies that 4.168/65 is unable to
bestow any mechanical integrity to the membrane. These data
thus enable us to identify an important role for spectrin-actin
binding domain ofprotein 4.1 in regulating mechanical stabil-
ity of the erythrocyte membrane. The presence of fragmented
cells in the circulation and the identification of a moderately
severe hemolytic anemia in these individuals further implies
that the erythrocytes in which 4.1 lacks the spectrin-actin bind-
ing domain are also functionally defective in vivo. Our ability
to improve the mechanical stability of unstable 4.168/65 mem-
branes by reconstitution with normal 4.1 implies that normal
4.1 is able to interact with functional sites on the membranes
that are unoccupied by the mutant protein. However, our find-
ing that the mechanical stability of these membranes can be
restored to only 80% of normal, while the mechanical stability
of 4.1 -deficient membranes can be restored to normal levels
suggests that the mutant 4.1 already assembled on the mem-
brane may, either sterically or by other mechanisms, limit the
accessibility to all the functional binding sites.
The combined biochemical, immunologic and functional
studies performed on the two mutant forms of protein 4.1-as-
sociated hereditary elliptocytosis have enabled us to document
the importance of the spectrin-actin binding domain in regu-
lating mechanical stability of the erythrocyte membrane. Re-
cently, protein 4.1 has been found in platelets, polymorpho-
nuclear leukocytes, lymphocytes, fibroblasts, lens, and brain
(23-30). However, in contrast to erythrocyte proteins, the
function of nonerythroid protein 4.1 has not yet been defined.
Studies on nonerythroid protein 4.1 isolated from cells of our
patients with mutant proteins might shed light on the role of
this structural protein in these cells.
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